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152 drug na¨ ıve primary hypothyroid patients were divided into morning (Group 1) and evening (Group 2) dosing group and
evaluated for change in biochemical proﬁle, physical functioning and Quality of Life during the course of 12 weeks of study. At
the end of 12 weeks 70 (90.90%) subjects in Group 1 and 72 (96%) in Group 2 achieved euthyroidism. On evaluation clinical
symptoms and total clinical scores improved in both the groups at the end of 6 and 12 weeks. Signiﬁcant improvement in thyroid
proﬁle was seen in both the groups at the end of 6 and 12 weeks (P value <.0001). On intergroup comparison, no signiﬁcant
diﬀerence in thyroid proﬁle was seen at 6 and 12 weeks between the morning and the evening dose group. Similar dose of
levothyroxine was required to achieve euthyroidism in both the groups. Though an early restoration of euthyroidism was seen
in evening group, the diﬀerence when compared to the morning group was not statistically signiﬁcant. On assessment of QoL,
statistically signiﬁcant improvement in various parameters was seen in both the groups. Hence, from the study we inferred that
evening dose is as eﬃcacious as morning dose and provides an alternate dosing regimen.
1.Introduction
Hypothyroidism is a common endocrine disorder resulting
from deﬁciency of thyroid hormone. The prevalence of overt
hypothyroidism increases with age, with more than 10%
of the women of over 60 years having subclinical hypothy-
roidism [1, 2]. Whether primary or secondary, treatment of
choice is Levothyroxine sodium. The primary advantage of
Levothyroxine therapy is that the peripheral deiodination
mechanism can contribute to produce the amount of T3
required under physiological control. Following oral admin-
istration, the absorption of levothyroxine is incomplete and
variable, especially when taken with food. The amount
absorbed decreases from 80% in the fasting state to 60%
in the fed state [3]. Interference with Levothyroxine has
been documented with cholestyramine resin, sucralphate,
iron sulphate, calcium preparations, aluminum antacids,
raloxifene, activated charcoal, various soya products, and
food and herbal remedies [4–7]. Also ﬁber-enriched diet,
the traditional Indian diet, has been shown to adversely
aﬀect the absorption of Levothyroxine [8]. Intake of coﬀee
in early morning is a social habit in this part of the country,
which may interfere with the absorption of levothyroxine
[9]. So as convention the drug is given at least half an hour
before breakfast, and failure to follow this advice results
in variable absorption of levothyroxine sodium. However,
many patients with hypothyroidism ﬁnd it inconvenient
to take the drug on an empty stomach in the morning
because of their lifestyle, and intake of multiple other drugs
which they are regularly consuming and often request their
treating physicians to prescribe the drug at some alternate
time of the day. The results of the study conducted by Bolk
et al. [10] in which they showed a marked improvement
in the thyroid hormone proﬁle of twelve patients after
switching from morning to the evening dose, prompted
us for further investigation. They found it to be safe and
well tolerated. They found out that changing the timings
of thyroxine ingestion does not aﬀect the circadian rhythm2 Journal of Thyroid Research
of TSH and iodothyronine secretion, and hence, testing the
thyroid proﬁle of the patients in the morning after ingesting
levothyroxine at night bears no signiﬁcance in the outcome
of the study. Keeping these facts in mind, this study was
planned to compare the eﬃcacy of morning versus bedtime
dose of thyroxine in patients of hypothyroidism.
2.MaterialsandMethods
The study was conducted with 77 newly diagnosed drug
na¨ ıve subjects in group 1 and 75 in group 2, who were
randomly selected from the patients attending “Endocrinol-
ogy Clinic” at PGIMS Rohtak. All patients were having
Hashimoto’s thyroiditis as underlying cause of hypothy-
roidism. A written consent was taken from all patients.
Patients in group 1 were given levothyroxine in the morning
minimum half an hour before breakfast, and in group 2
the drug was given minimum 2 hours after dinner. None
of the patients used medication known to interfere with
levothyroxine absorption, nor were they known to have
gastro-intestinal disease. Pregnant and postpartum patients
with hypothyroidism were not included in either group.
Initial dosage was calculated as 1.6mcg/kg body weight,
and the closest commercially available dosage, that is,
75/100/125mcg was started. In the event of nonachievement
of euthyroidism (deﬁned by normalization of T4 and
TSH) at the end of six weeks, the dose was increased by
25mcg/day. The study was carried for a time period of
12 weeks, and assessment of quality of life (by RAND-
(Research and Development) 36 scoring system [11]) and
clinical proﬁle (according to the clinical scores given by
Billewicz et al. [12]) were done at baseline, two, six and
12 weeks. Biochemical parameters were assessed at baseline
(before start of treatment) and at the end of six, and 12
weeks. fT3 (normal range—2.4–4.2 pg/mL) and fT4 (normal
range—0.89–1.76ng/dL)wereassessedbychemiluminescent
method using analyzer and kits of Siemens (ADIVA Centaur
CP). TSH (normal range 0.34–4.25 mIU/L) was done by
immunometric assay (PC RIA MAS by Startek) by Turbo
TSH [125I] using IRMAkit. Lipid proﬁle was assessed by
Konelab 30i using analyzing kits by Randox. Patients were
studied on the basis of change in clinical symptoms at
presentation, improvement in Quality of life and change in
the biochemical parameters with special reference to thyroid
function tests and lipid proﬁle. Clinical symptoms were
scored according to the scoring system given by Billewicz et
al. [12]. Quality of life was assessed by RAND 36 [11]w h i c h
measured health according to eight subscales which are:
physical functioning, role limitation due to physical health,
role limitation due to emotional problems, energy/fatigue,
emotional wellbeing, social functioning, pain and general
health. The scale score ranged from 0 to 100 for every sub-
scale, with a higher outcome meaning a better health status.
3.StatisticalAnalysis
Primary end point was a change in the thyroid proﬁle of
the subjects and achievement of euthyroidism in each group
measured at the end of six and 12 weeks. Secondary end
points of the study were change in QoL, thyroid symptom
score, and lipid proﬁle. For calculation of sample size, results
from the pilot study conducted by Bolk et al. was used
where it was found that to get a signiﬁcant diﬀerence in
TSH of 1 mIU/L in both the groups at the end of study
with a power of 80%, 75 subjects should be enrolled in each
group. Z test was used to compare the diﬀerence in mean
of free T3, free T4, and lipid proﬁle between each group
at the beginning, six and 12 weeks. Paired t-test was used
to assess the intragroup change at six and 12 weeks. The
value of TSH in either group did not follow Gaussian data
distributiononfollowupasmostofthedatawereclusteredin
a narrow range in both the groups at 6 weeks and 12 weeks.
Hence, nonparametric tests: Wilcoxon two-sample test was
applied for intergroup comparison and Wilcoxon sign-rank
test was applied for intragroup comparison. For intergroup
comparison of total score of clinical signs and symptoms and
QoL, Wilcoxon two-sample test was applied. For intragroup
comparison of total score of clinical signs and symptoms and
QoL,Wilcoxonsign-ranktestwasapplied.Thedatacollected
and analyzed is expressed as mean ± SD.
4. Observations andResults
The mean age of patients in group 1 was 32.84 ± 13.06 years
and that in group 2 was 35.76 ± 10.59 years with a mean
weightof60.94±15.58kgand62.76±13.15kgingroup1and
group 2, respectively, at baseline. At the end of 12 weeks the
mean weight was 60.21±15.69 and 62.28±13.35kg in group
1 and 2, respectively. There was no signiﬁcant diﬀerence in
body weight between the two groups both at baseline and at
the end of 12 weeks (P value = .92 and.92 at baseline and at
12 weeks, resp.). The sex ratio of male:female was 1:4.5 in
g r o u p1a n d1:6 . 9i ng r o u p2 .
In the current study, 101±15.8mcg of levothyroxine was
required in Group 1, and 100.40 ± 13.28mcg in Group 2
oflevothyroxinewasrequiredtoachieveeuthyroidism.There
was no statistically signiﬁcant diﬀerence in the amount of
drugusedinboththegroups(P value = .94).Itwasseenthat
atthe end of 6 weeks, 32 (41.55%) of subjectsin Group 1 and
35 (46.66%) of subjects in Group 2 achieved euthyroidism.
At the end of 12 weeks, 70 (90.90%) subjects in Group 1 and
72 (96%) in Group 2 achieved euthyroidism. We observed
that there was an early restoration of euthyroidism (TSH <
4.25mIU/L) in the group receiving levothyroxine as evening
dose. However, no statistically signiﬁcant diﬀerence was seen
at the end of 6 weeks and 12 weeks (P value = .51 and
.19). Improvement in thyroid proﬁle (increase in fT3 and
fT4 and decrease in TSH) at 6 weeks and 12 weeks was seen
both in the morning group as well as in the evening, and
it was highly signiﬁcant in comparison with their baseline
thyroid function (P value < .0001). However, on intergroup
comparison at the end of 6 and 12 weeks, no signiﬁcant
change in the thyroid proﬁle was seen (P value = .31 in both
fT4 and TSH at the end of 12 weeks) (Table 1). No patient in
either group had a low serum TSH at either 6 or 12 weeks.
We also analyzed the secondary outcomes of the study in
both of the groups. Total serum cholesterol levels decreased
signiﬁcantly in both of the groups at the end of 12 weeksJournal of Thyroid Research 3
Table 1: Comparison of biochemical parameters (data expressed as mean ± SD) of Group 1 and Group 2 at the end of 6 and 12wks.
Biochemical parameter Group 1 Group 2
Baseline 6wks 12wks Baseline 6wks 12wks
fT3 2.09 ±1.03 2.91 ±.75 3.48 ±1.09 2.15 ±1.03 2.93 ±1.01 3.20 ±0.54
(pg/mL) (P<. 0001) (P<. 0001) (P<. 0001) (P<. 0001)
fT4 0.72 ±0.59 1.31 ±0.45 1.5 ±0.33 0.74 ±0.51 .30 ±0.49 1.48 ±0.31
(ng/dL) (P<. 0001) (P<. 0001) (P<. 0001) (P<. 0001)
TSH 82.79 ±56.32 17.03 ±18.33 5.13 ±9.36 78.23 ±43.15 12.64 ±44.27 3.27 ±4.19
(mIU/L) (P<. 0001) (P<. 0001) (P<. 0001) (P<. 0001)
Triglyceride 158.50 ±89.36 141.17 ±62.4 141.10 ± 62.76 158.75 ±89.72 149.82 ±78.07 137.24 ±68.37
(mg/dL) (P = .08) (P = .08) (P = .50) (P = .09)
Cholesterol 194.95 ±63.21 182.19 ±44.27 177.66 ± 39.71 196.88 ±75.69 176.64 ±38.35 173.85 ±38.25
(mg/dL) (P = .48) (P = .012) (P = .029) (P = .015)
HDL 43.25 ±20.76 39.88 ±64 4 .36 ±15.74 42.84 ±12.91 41.56 ±12.91 43.29 ±12.14
(mg/dL) (P = .14) (P = .311) (P = .54) (P = .88)
LDL 119.44 ±48.08 112.88 ±34.48 108.59 ± 33.45 113.06 ±40.05 105.79 ±29.85 103.68 ±31.27
(mg/dL) (P = .29) (P = .56) (P = .27) (P = .65)
VLDL 30.86 ±17.79 29.19 ±14.11 28.31 ±13.13 31.54 ±15.80 29.20 ±12.69 27.44 ±15.33
(mg/dL) (P = .19) (P = .34) (P = .13) (P = .76)
when compared to their baseline (P value = .01 for both
of the groups). However, when Group 1 was compared
to Group 2, there was no signiﬁcant statistical diﬀerence.
There was a reduction of 8% cholesterol in Group 1 and
11.7% in Group 2. Serum triglyceride levels were reduced
by 10.9% in group 1 and 13.5% in group 2. The study
also revealed that there was a reduction in LDL in both the
groups (9% in group 1 and 8.8% in group 2). However,
there was no statistical signiﬁcant improvement in LDL and
serum triglyceride levels when intragroup and intergroup
c o m p a r i s o nw a sm a d e( Table 1).
In our study we observed that physical tiredness,
followed by mental lethargy, muscle pain, and increase in
body weight were the most common symptoms in patients
of group 1, whereas periorbital puﬃness was the most
common sign. Similarly in group 2, physical tiredness was
the most common presenting symptom, followed by mental
lethargy, muscle pain, and dryness of hair, while slowing
of ankle jerk and slow movements were the most common
signs observed. Among the male patients, it was seen that in
both the groups, physical tiredness was the most common
symptom (72% in group 1 and 90% in group 2) whereas
periorbital puﬃness and slowing of ankle jerk were the
most common signs in group 1 and group 2, respectively.
The total clinical scores decreased signiﬁcantly in both
the groups (showing improvement) (P value of .0001
and.0005 in group 1 and 2, resp., when compared to their
baseline at the end of 12 weeks), but the diﬀerence was
not statistically signiﬁcant when the morning group was
compared to the evening group (P value = .37 and .31 at
the end of 6 and 12 weeks, resp.). Physical tiredness was the
most common symptom to be resolved after 12 weeks of
therapy, and periorbital puﬃness in Group1 and slowness of
movement in Group 2 were the most common signs which
had maximum improvement after 12 weeks of therapy.
On evaluation of the results of assessment of quality of
life by RAND-36 scoring system, it was seen that all the
parameters decreased in both the groups. It was noticed that
there was a signiﬁcant improvement in terms of physical
functioning and role limitation due to physical health in
both the groups at the end of 12 weeks when compared to
its baseline. It was also found that there was a signiﬁcant
improvement in the role limitation due to emotional prob-
lems in group 2 at the end of 12 weeks when compared to
its baseline. No signiﬁcant results were found in group 1.
Improvement in the rest of the parameters was found to be
statistically insigniﬁcant in both the groups. Scores of social
functioning was found to be markedly improved in group 1
when it was compared to that of group 2 at the end of 2, 6,
and 12 weeks.
5. Discussion
The present study shows noninferiority of the evening dose
of levothyroxine when compared to the morning dose in
terms of improvement in signs and symptoms, quality of
life, and dosage of the drug required for achievement of
euthyroidism. Marked improvement in thyroid proﬁle was
seen in both the groups. Improvement in total cholesterol,
LDL, and serum triglyceride levels was seen in both the
groups, and the diﬀerence between the groups was not
signiﬁcant. The results of our study give the patients a choice
of timings of their daily intake of drug. In modern day busy
world, thismay proveboon tomillions ofpeople, whodueto
their busy schedule or intake of other drugs in the morning
hours were not able to adhere to the requirements of fasting
morning intake of levothyroxine.
The mean dose of levothyroxine required to achieve eut-
hyroidism and the number of patients who achieved euthy-
roidism at 12 weeks were slightly better in the bedtime4 Journal of Thyroid Research
treatment group, although neither of these parameters were
signiﬁcantly diﬀerent from the morning dose group. We
attribute our ﬁndings to better availability of the drug at
night due to slowness of gastric motility, noninterference
with breakfast and circadian rhythm, and activity of deio-
dinase which might alter the metabolism of the drug in the
body [13–16]. Findings of present study are in contrast to
the study done by Huynh et al. [17] where they had shown
that nonfasting regimen of levothyroxine administration
are associated with higher and more variable serum TSH
concentrations, and if a speciﬁc serum TSH goal is desired,
thereby avoiding iatrogenic subclinical thyroid disease, then
fasting ingestion ensures that TSH concentration remain
within narrowest target range. The noninferiority of night-
time administration of levothyroxine in our study can be
explained by the fact that ingesting drug at least two hours
after dinner, eating nothing thereafter, and going to the bed
provides several hours of empty stomach to the drug in
contrast to ingesting breakfast half an hour after morning
administration of drug and will result in at least similar if
not better bioavailability of drug. Recently Bolk et al. [18]
also published the results of their study involving ninety
patients where they compared the eﬀects of morning versus
evening administration of levothyroxine sodium. This study
showed that levothyroxine taken at bedtime signiﬁcantly
improved thyroid hormone levels, but quality of life param-
eters and plasma lipids showed no signiﬁcant change as
compared to morning intake. These ﬁndings strengthens
the observation of present study that although bedtime
administration of levothyroxine is statically not superior to
morning fasting administration, but it is also not inferior to
morningadministrationasfarastotaldoseneededtoachieve
euthyroidism, number of patients achieving euthyroidism
at 12 weeks and with respect to improvement in quality
of life parameter and lipid proﬁle. Strength of the present
study is the fact that it involves larger number of patients
as compared to all previous studies who had no earlier
exposure to levothyroxine. Hence, the results of our study
are more practical and closer to the real world scenario.
Moreover, majority of the patients taking levothyroxine as
evening/bedtime dose in the present study ﬁnd it more
convenient and decided to continue with evening/bedtime
administration at the end of the study.
An important matter of concern was impact of levothy-
roxine on circadian rhythm and nocturnal TSH surge when
given as evening dose and whether sample for determining
thyrotropin levels can be taken in the morning after night-
time administration of levothyroxine. The serum levels of
TSH increase in the evening, reach a maximum near sleep
onset, and are followed by a progressive decrease during the
night and low values during the day [19]. The percentage
nocturnal rise of TSH is 71 ± 40% in healthy controls
and is maintained in euthyroid patients on levothyroxine
therapy taken in the morning (63 ± 51%) and patients
with mild hypothyroidism (54 ± 33%), whereas in overt
hypothyroidism, this nocturnal surge disappears [20]. Bolk
et al. [10] in their pilot study found no change in the
circadian rhythm of TSH when switching the time of
levothyroxine ingestion to bedtime. There was no signiﬁcant
change in T4, rT3, albumin, and TBG serum levels, or in
the T3/rT3 ratio. The relative amplitude and time of the
nocturnal TSH surge remained intact. Moreover, Persani
et al. [21] showed that bioactivity of TSH has a circadian
variation with less bioactive and diﬀerently glycosylated
TSH molecules secreted during night. These ﬁndings bear
important practical consequences in our study as the timings
for blood sampling for monitoring thyroid hormones can
still be done in the morning as per present norm even if the
patient is taking levothyroxine as evening dose.
Our data do not allow us to conclude that ingestion
of levothyroxine 2 hours after the evening meal provides a
suﬃciently long interval to avoid the interfering eﬀects of
food on levothyroxine absorption. Although subjects were
instructed to take their levothyroxine at least 2 hours after
dinner, we did not collect data on the exact interval between
dinner and levothyroxine ingestion in the bedtime-dosing
subjects, and thus, we do not know if the average meal-dose
interval was closer to 2, 3, or 4 hours, or longer. Meal-dose
intervals of greater than 2 hours may be necessary to assure
an empty stomach at the time of levothyroxine ingestion,
particularly when the preceding evening meal contained
solid and/or fatty foods.
From the study we inferred that there was at least
similar bioavailability and metabolism of the drug either
given as morning or evening dose. So in a nutshell, we can
say that evening dose is as eﬃcacious as morning dose in
improvementofthyroidproﬁle,reductionintotalcholesterol
levels, improvement of clinical signs and symptoms, and
improvement in quality of life. In the modern busy life
with hectic morning schedule, the results give hope for an
alternate dosing regimen.
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